J. B. Chemicals & Pharmaceuticals Limited
JBCHEPHARM.NS
National Stock Exchange of India2,444.50
INR
+8.70
- -
J. B. Chemicals & Pharmaceuticals Limited
JBCHEPHARM.NS
(National Stock Exchange of India)
Recent
price
2,444.50
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- J. B. Chemicals & Pharmaceuticals Limited manufactures and markets a broad portfolio of pharmaceutical formulations across more than 20 therapeutic areas including gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynecology, dental care, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesics, dermatology, antivirals, lozenges, and contrast media; key brands encompass Rantac and Metrogyl in gastroenterology and anti-infectives, Cilacar and Nicardia in hypertension, Cadomer in wound care and dermatology, along with specialized offerings such as proton pump inhibitors, antibiotics in oral/injectable/topical forms, calcium channel blockers, DPP-4 inhibitors, ketoanalogues for renal care, lozenges as the third-largest global manufacturer, and contrast agents for imaging. The company operates primarily in India with distribution through 600,000 pharmacies nationwide, exports to over 40 regulated and semi-regulated markets including the USA, and maintains wholly owned subsidiaries in South Africa and Russia; it serves healthcare providers and patients via eight state-of-the-art manufacturing facilities compliant with USFDA and WHO standards, focusing on chronic therapies, contract development and manufacturing organization services particularly in medicated lozenges, and incremental innovation for lifecycle management. Founded in 1976 and headquartered in Mumbai, India, J. B. Chemicals & Pharmaceuticals has pursued aggressive inorganic growth through five acquisitions in India over the past two years including the Razel franchise from Glenmark in 2024 and approximately 15 ophthalmology drugs from Novartis for INR 1,089 crore in late 2024 to enter the high-growth ophthalmology segment comprising anti-infectives, anti-allergies, and glaucoma treatments effective from January 2027; most recently in June 2025, Torrent Pharmaceuticals agreed to acquire a controlling 46.39% stake from KKR for INR 11,917 crore at an equity valuation of INR 25,689 crore followed by a mandatory open offer and subsequent merger, pending regulatory approvals including from SEBI, CCI, and NCLT, to create a diversified platform enhancing Torrent's Indian branded formulations presence and JB's CDMO capabilities.